Literature DB >> 2448232

Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion.

A L Petzer1, T F Schulz, R Stauder, A Eigentler, B L Myones, M P Dierich.   

Abstract

The receptor for the C3d fragment of the third component of complement, CR2, has recently been shown also to act as the receptor for the Epstein-Barr virus (EBV) and to be involved in the control of B-cell proliferation. In order to define functionally important domains on this molecule, we produced monoclonal antibodies to several distinct epitopes. CR2 was purified from a NP-40 lysate of human tonsils by a new method involving sequential chromatography on lentil lectin Sepharose 4B and DEAE-Sephadex and used to immunize mice. After fusion we obtained four stable hybridoma lines producing antibody to CR2. Specificity of these antibodies for CR2 was ascertained by immunofluorescence analysis on a panel of various cells known to possess CR2, by their reactivity in a recently described ELISA for C3 receptors, by Western blotting with purified CR2 and immunoprecipitation from 125I-labelled Raji cells. These four antibodies were found to recognize three distinct epitopes localized on the same fragments of 95,000, 72,000, 50,000, 32,000 and 28,000 MW obtained after mild tryptic digestion of CR2. The 72,000 MW fragment contains the binding site for C3d. Two monoclonal antibodies recognizing the same epitope did not inhibit the binding of C3d-coated sheep erythrocytes to Raji cells, whereas the other two antibodies against distinct epitopes did inhibit in the presence of a second antibody. All four monoclonal antibodies stimulated the proliferation of human peripheral blood B cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448232      PMCID: PMC1454684     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.

Authors:  G R Nemerow; M E McNaughton; N R Cooper
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

2.  Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule.

Authors:  R Frade; M C Crevon; M Barel; A Vazquez; L Krikorian; C Charriaut; P Galanaud
Journal:  Eur J Immunol       Date:  1985-01       Impact factor: 5.532

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

5.  gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor.

Authors:  R Frade; M Barel; B Ehlin-Henriksson; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

6.  Epstein-Barr virus receptors on human pharyngeal epithelia.

Authors:  L S Young; D Clark; J W Sixbey; A B Rickinson
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

7.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

8.  Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function.

Authors:  T F Schulz; O Scheiner; J Alsenz; J D Lambris; M P Dierich
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

9.  Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H.

Authors:  J Alsenz; T F Schulz; J D Lambris; R B Sim; M P Dierich
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

View more
  8 in total

Review 1.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach.

Authors:  J K Chan; C S Ng; P G Isaacson
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

3.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

4.  Diffuse lymphocyte-predominant Hodgkin's disease (diffuse paragranuloma). A variant of the B-cell-derived nodular type.

Authors:  M L Hansmann; H Stein; F Dallenbach; C Fellbaum
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

5.  Development, maturation and subsequent activation of follicular dendritic cells (FDC): immunohistochemical observation of human fetal and adult lymph nodes.

Authors:  Naoko Kasajima-Akatsuka; Kunihiko Maeda
Journal:  Histochem Cell Biol       Date:  2006-02-10       Impact factor: 4.304

6.  Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells.

Authors:  Ru Jiang; Xin Gu; Cherie-Ann Nathan; Lindsey Hutt-Fletcher
Journal:  J Oral Pathol Med       Date:  2008-08-15       Impact factor: 4.253

7.  C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3.

Authors:  A Eigentler; T F Schulz; C Larcher; E M Breitwieser; B L Myones; A L Petzer; M P Dierich
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

8.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.